Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Current Development of Vaccines for Respiratory Viral Infection
share announcement

Current Development of Vaccines for Respiratory Viral Infection

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1238

Special Issue Editor

Dr. Ting Shi

E-Mail Website
Guest Editor
Edinburgh Medical School, Edinburgh, UK
Interests: epidemiology; respiratory disease; respiratory syncytial virus; influenza; SARS-CoV-2; global health; vaccination; individual patient data meta-analysis; national linked dataset; big data analysis

Special Issue Information

Dear Colleagues,

Viral respiratory tract infections constitute a substantial disease burden in the population, particularly among young children and older adults. More than 25 viruses have been linked to respiratory infections, including common respiratory pathogens such as rhinovirus (RV), respiratory syncytial virus (RSV), influenza virus (Flu), human metapneumovirus (hMPV), parainfluenza viruses (PIV) and human coronaviruses (CoVs). This Special Issue of Vaccines focuses on the most recent progress and current vaccine development trends in the field of respiratory viral infection. We invite you to contribute with an original research article, review or perspective on the latest research to highlight novel experimental vaccine candidates, scientific data on supporting vaccine strategies, immune responses elicited by a novel vaccine and concerns and optimisations relating vaccine strategies. This Special Issue emphasises major infectious diseases caused by respiratory viruses, but related topics on co-infections are also welcomed. We look forward to receiving your contributions.

Dr. Ting Shi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 3210 KiB  
Article
Development of a Cell-Based Reporter Potency Assay for Live Virus Vaccines
by Dengyun Sun, Brian K. Meyer, Dhanvanthri S. Deevi, Asra Mirza, Li He, Ashley Gruber, Susan J. Abbondanzo, Noah A. Benton, Melissa C. Whiteman, Robert C. Capen and Kevin B. Gurney
Vaccines 2024, 12(7), 769; https://doi.org/10.3390/vaccines12070769 - 13 Jul 2024
Viewed by 371
Abstract
The rapid development of potency assays is critical in the development of life-saving vaccines. The traditional plaque assay or fifty percent tissue culture infectious dose (TCID50) assay used to measure the potency of live virus vaccines is time consuming, labor intensive, [...] Read more.
The rapid development of potency assays is critical in the development of life-saving vaccines. The traditional plaque assay or fifty percent tissue culture infectious dose (TCID50) assay used to measure the potency of live virus vaccines is time consuming, labor intensive, low throughput and with high variability. Described here is the development and qualification of a cell-based reporter potency assay for two vaccines for respiratory viral infection, one based on the recombinant vesicular stomatitis virus (rVSV) backbone, termed Vaccine 1 in this paper, and the other based on the measles virus vector, termed Vaccine 2. The reporter potency assay used a Vero E6 cell line engineered to constitutively express NanuLuc® luciferase, termed the VeroE6-NLuc or JM-1 cell line. Infection of JM-1 cells by a live virus, such as rVSV or measles virus, causes a cytopathic effect (CPE) and release of NanuLuc® from the cytoplasm into the supernatant, the amount of which reflects the intensity of the viral infection. The relative potency was calculated by comparison to a reference standard using parallel line analysis (PLA) in a log–log linear model. The reporter assay demonstrated good linearity, accuracy, and precision, and is therefore suitable for a vaccine potency assay. Further evaluation of the Vaccine 1 reporter assay demonstrated the robustness to a range of deliberate variation of the selected assay parameters and correlation with the plaque assay. In conclusion, we have demonstrated that the reporter assay using the JM-1 cell line could be used as a potency assay to support the manufacturing and release of multiple live virus vaccines. Full article
(This article belongs to the Special Issue Current Development of Vaccines for Respiratory Viral Infection)
►▼ Show Figures

Figure 1

15 pages, 1415 KiB  
Article
A Live Attenuated H1N1 Influenza Vaccine Based on the Mutated M Gene
by Yinglei Yi, Hongbo Zhang, Youcai An and Ze Chen
Vaccines 2024, 12(7), 725; https://doi.org/10.3390/vaccines12070725 - 29 Jun 2024
Viewed by 514
Abstract
The influenza vaccines currently approved for clinical use mainly include inactivated influenza virus vaccines and live attenuated influenza vaccines (LAIVs). LAIVs have multiple advantages, such as ease of use and strong immunogenicity, and can provide cross-protection. In this study, the M gene of [...] Read more.
The influenza vaccines currently approved for clinical use mainly include inactivated influenza virus vaccines and live attenuated influenza vaccines (LAIVs). LAIVs have multiple advantages, such as ease of use and strong immunogenicity, and can provide cross-protection. In this study, the M gene of the PR8 virus was mutated as follows (G11T, C79G, G82C, C85G, and C1016A), and a live attenuated influenza virus containing the mutated M gene was rescued and obtained using reverse genetic technology as a vaccine candidate. The replication ability of the rescued virus was significantly weakened in both MDCK cells and mice with attenuated virulence. Studies on immunogenicity found that 1000 TCID50 of mutated PR8 (mPR8) can prime strong humoral and cellular immune responses. Single-dose immunization of 1000 TCID50 mPR8 was not only able to counter the challenge of the homologous PR8 virus but also provided cross-protection against the heterologous H9N2 virus. Full article
(This article belongs to the Special Issue Current Development of Vaccines for Respiratory Viral Infection)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop